Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALSTARS: COYA 302 for the Treatment of ALS
NCT07161999Phase 3Active, not recruiting
- Sponsor
- Coya Therapeutics, Inc.
- Start
- Oct 2025
- Primary completion
- Apr 2027
- Modality
- Cytokines & Interferons, Fc Fusion Proteins, Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 3 trial of COYA-302 in amyotrophic lateral sclerosis (ALS), sponsored by Coya Therapeutics, Inc.. Started Oct 2025; status: active, not recruiting.
02
Drugs
COYA-302
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07161999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07161999.